Stay updated with breaking news from Synthimed Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Synthimed Labs is a recently incorporated company, set up to facilitate the proposed combination, and it is not engaged in any business activities as on date.
Ind-Swift was admitted for corporate insolvency on September 12 on a petition by trader creditor Allcare Containers claiming overdues of ₹3.12 crore, according to an order passed by the Chandigarh National Company Law Tribunal (NCLT). Last week, the NCLAT stayed the insolvency process till October 30 after the company said that it had settled the principal dues of Allcare but needed time to negotiate the terms of interest payment.
Ind Swift Laboratories has sold its API and CRAMS businesses to Synthimed Labs for ₹1,650 crores.
India Business News: MUMBAI: Ind-Swift Labs said it will sell its active pharmaceutical ingredient (API) and contract research & manufacturing services (CRAMS) business to.
India's Ind-Swift Laboratories said on Wednesday it would sell its active pharmaceuticals ingredients and contract research and manufacturing services business to Synthimed Labs in a deal with...